177 related articles for article (PubMed ID: 15583517)
1. Ziprasidone: first year experience in a hospital setting.
Centorrino F; MacLean E; Salvatore P; Kidwell JE; Fogarty KV; Berry JM; Baldessarini RJ
J Psychiatr Pract; 2004 Nov; 10(6):361-7. PubMed ID: 15583517
[TBL] [Abstract][Full Text] [Related]
2. Effects of high-dose ziprasidone and haloperidol on the QTc interval after intramuscular administration: a randomized, single-blind, parallel-group study in patients with schizophrenia or schizoaffective disorder.
Miceli JJ; Tensfeldt TG; Shiovitz T; Anziano RJ; O'Gorman C; Harrigan RH
Clin Ther; 2010 Mar; 32(3):472-91. PubMed ID: 20399985
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and tolerability of oral ziprasidone in psychiatric inpatients with an acute exacerbation of schizophrenia or schizoaffective disorder: a multicenter, prospective, and naturalistic study.
Díaz-Marsá M; Sánchez S; Rico-Villademoros F;
J Clin Psychiatry; 2009 Apr; 70(4):509-17. PubMed ID: 19358789
[TBL] [Abstract][Full Text] [Related]
4. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.
Simpson GM; Glick ID; Weiden PJ; Romano SJ; Siu CO
Am J Psychiatry; 2004 Oct; 161(10):1837-47. PubMed ID: 15465981
[TBL] [Abstract][Full Text] [Related]
5. Ziprasidone and the corrected QT interval: a comprehensive summary of clinical data.
Camm AJ; Karayal ON; Meltzer H; Kolluri S; O'Gorman C; Miceli J; Tensfeldt T; Kane JM
CNS Drugs; 2012 Apr; 26(4):351-65. PubMed ID: 22452529
[TBL] [Abstract][Full Text] [Related]
6. Effects of Oral Ziprasidone and Oral Haloperidol on QTc interval in patients with Schizophrenia or Schizoaffective disorder.
Miceli JJ; Tensfeldt TG; Shiovitz T; Anziano R; O'Gorman C; Harrigan RH
Pharmacotherapy; 2010 Feb; 30(2):127-35. PubMed ID: 20099987
[TBL] [Abstract][Full Text] [Related]
7. [Switching patients with schizophrenia to ziprasidone from conventional or other atypical antipsychotics].
Bartkó G; Trixler M; Bitter I; Degrell I; Füredi J; Faludi G;
Neuropsychopharmacol Hung; 2006 Dec; 8(4):201-9. PubMed ID: 17211055
[TBL] [Abstract][Full Text] [Related]
8. Ziprasidone in the management of schizophrenia : the QT interval issue in context.
Taylor D
CNS Drugs; 2003; 17(6):423-30. PubMed ID: 12697001
[TBL] [Abstract][Full Text] [Related]
9. Ziprasidone: the fifth atypical antipsychotic.
Caley CF; Cooper CK
Ann Pharmacother; 2002 May; 36(5):839-51. PubMed ID: 11978164
[TBL] [Abstract][Full Text] [Related]
10. Ziprasidone and the QTc interval: pharmacokinetic and pharmacodynamic considerations.
Kelly DL; Love RC
Psychopharmacol Bull; 2001; 35(4):66-79. PubMed ID: 12397857
[TBL] [Abstract][Full Text] [Related]
11. Ziprasidone: an atypical antipsychotic drug for the treatment of schizophrenia.
Stimmel GL; Gutierrez MA; Lee V
Clin Ther; 2002 Jan; 24(1):21-37. PubMed ID: 11833834
[TBL] [Abstract][Full Text] [Related]
12. From clinical research to clinical practice: a 4-year review of ziprasidone.
Nemeroff CB; Lieberman JA; Weiden PJ; Harvey PD; Newcomer JW; Schatzberg AF; Kilts CD; Daniel DG
CNS Spectr; 2005 Nov; 10(11 Suppl 17):1-20. PubMed ID: 16381088
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial.
Addington DE; Pantelis C; Dineen M; Benattia I; Romano SJ
J Clin Psychiatry; 2004 Dec; 65(12):1624-33. PubMed ID: 15641867
[TBL] [Abstract][Full Text] [Related]
14. Drug safety evaluation of ziprasidone.
Citrome L
Expert Opin Drug Saf; 2011 May; 10(3):437-48. PubMed ID: 21332416
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of switching to ziprasidone in italian patients with acute exacerbation of schizophrenia: an open-label trial.
Mencacci C;
Pharmacopsychiatry; 2012 Sep; 45(6):236-40. PubMed ID: 22592506
[TBL] [Abstract][Full Text] [Related]
16. No significant QTc interval changes with high-dose ziprasidone: a case series.
Levy WO; Robichaux-Keene NR; Nunez C
J Psychiatr Pract; 2004 Jul; 10(4):227-32. PubMed ID: 15552544
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness, tolerability, and safety of ziprasidone in patients with schizophrenia or schizoaffective disorder: results of a multi-centre observational trial.
Kudla D; Lambert M; Domin S; Kasper S; Naber D
Eur Psychiatry; 2007 Apr; 22(3):195-202. PubMed ID: 17140769
[TBL] [Abstract][Full Text] [Related]
18. Single-dose ziprasidone associated with QT interval prolongation.
Witsil JC; Zell-Kanter M; Mycyk MB
Am J Emerg Med; 2012 Jun; 30(5):837.e1-2. PubMed ID: 21641143
[TBL] [Abstract][Full Text] [Related]
19. An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder.
Goff DC; Posever T; Herz L; Simmons J; Kletti N; Lapierre K; Wilner KD; Law CG; Ko GN
J Clin Psychopharmacol; 1998 Aug; 18(4):296-304. PubMed ID: 9690695
[TBL] [Abstract][Full Text] [Related]
20. Spotlight on ziprasidone in schizophrenia and schizoaffective disorder.
Gunasekara NS; Spencer CM; Keating GM
CNS Drugs; 2002; 16(9):645-52. PubMed ID: 12153335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
